Multicenter, Open-Label Study of Long-Term Topiroxostat (FYX-051) Administration in Japanese Hyperuricemic Patients with or Without Gout

BACKGROUND AND OBJECTIVES: Topiroxostat—a novel selective xanthine oxidoreductase inhibitor—has been reported to reduce serum urate levels. The purpose of this study was to assess the efficacy and safety of long-term topiroxostat administration in Japanese hyperuricemic patients with or without gout...

Descripción completa

Detalles Bibliográficos
Autores principales: Hosoya, Tatsuo, Ishikawa, Tomohiko, Ogawa, Yoshimi, Sakamoto, Ryusuke, Ohashi, Tetsuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2018
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6267543/
https://www.ncbi.nlm.nih.gov/pubmed/30219951
http://dx.doi.org/10.1007/s40261-018-0699-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6267543/
https://www.ncbi.nlm.nih.gov/pubmed/30219951
http://dx.doi.org/10.1007/s40261-018-0699-0

Ejemplares similares